|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0023449,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0087111,
umls-concept:C0242596,
umls-concept:C0439590,
umls-concept:C0599894,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1521828,
umls-concept:C1521840,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1722284,
umls-concept:C2911692
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-6-20
|
|
pubmed:abstractText |
Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In acute lymphoblastic leukemia (ALL), persistence or relapse of minimal residual disease (MRD) after chemotherapy indicates resistance to chemotherapy and results in hematologic relapse. A phase II clinical study was conducted to determine the efficacy of blinatumomab in MRD-positive B-lineage ALL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BaeuerlePatrick APA,
pubmed-author:BargouRalf CRC,
pubmed-author:BrüggemannMonikaM,
pubmed-author:BurmeisterThomasT,
pubmed-author:DegenhardEvelynE,
pubmed-author:EinseleHermannH,
pubmed-author:GökbugetNicolaN,
pubmed-author:GoebelerMarieleM,
pubmed-author:HoelzerDieterD,
pubmed-author:HorstHeinz-AHA,
pubmed-author:Köhne-VollandRudolfR,
pubmed-author:KlingerMatthiasM,
pubmed-author:KnebaMichaelM,
pubmed-author:KuferPeterP,
pubmed-author:LutterbueseRalfR,
pubmed-author:NagorsenDirkD,
pubmed-author:NeumannSvenjaS,
pubmed-author:OttmannOliverO,
pubmed-author:PfeiferHeikeH,
pubmed-author:RaffThorstenT,
pubmed-author:ReinhardtCarstenC,
pubmed-author:RiethmüllerGertG,
pubmed-author:SchaichMarkusM,
pubmed-author:SchmidMathiasM,
pubmed-author:SchmidtMargitM,
pubmed-author:StelljesMatthiasM,
pubmed-author:ToppMax SMS,
pubmed-author:ViardotAndreasA,
pubmed-author:ZugmaierGerhardG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2493-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21576633-Adult,
pubmed-meshheading:21576633-Agammaglobulinemia,
pubmed-meshheading:21576633-Aged,
pubmed-meshheading:21576633-Aged, 80 and over,
pubmed-meshheading:21576633-Antibodies, Bispecific,
pubmed-meshheading:21576633-Antibody Specificity,
pubmed-meshheading:21576633-Antigens, CD19,
pubmed-meshheading:21576633-Antigens, CD3,
pubmed-meshheading:21576633-Antigens, Neoplasm,
pubmed-meshheading:21576633-B-Lymphocytes,
pubmed-meshheading:21576633-Bone Marrow,
pubmed-meshheading:21576633-Cell Lineage,
pubmed-meshheading:21576633-Combined Modality Therapy,
pubmed-meshheading:21576633-Disease-Free Survival,
pubmed-meshheading:21576633-Drug Delivery Systems,
pubmed-meshheading:21576633-Drug Resistance, Neoplasm,
pubmed-meshheading:21576633-Female,
pubmed-meshheading:21576633-Humans,
pubmed-meshheading:21576633-Immunotherapy,
pubmed-meshheading:21576633-Kaplan-Meier Estimate,
pubmed-meshheading:21576633-Lymphocyte Activation,
pubmed-meshheading:21576633-Lymphopenia,
pubmed-meshheading:21576633-Male,
pubmed-meshheading:21576633-Middle Aged,
pubmed-meshheading:21576633-Molecular Targeted Therapy,
pubmed-meshheading:21576633-Neoplasm, Residual,
pubmed-meshheading:21576633-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:21576633-Remission Induction,
pubmed-meshheading:21576633-T-Cell Antigen Receptor Specificity,
pubmed-meshheading:21576633-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:21576633-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
|
|
pubmed:affiliation |
Comprehensive Cancer Center Mainfranken, University Wuerzburg, Germany.
|
